Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
THIOSULFIL (sulfamethizole) is an oral sulfonamide antibiotic approved in 1953 for bacterial infections. It is a small-molecule antimicrobial agent that inhibits bacterial folate synthesis. The product treats various bacterial infections via systemic absorption when taken orally.
Declining portfolio asset with minimal team investment; career growth limited unless assigned to legacy product rationalization or specialty infectious disease segments.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on THIOSULFIL offers limited career acceleration; roles focus on portfolio management, regulatory maintenance, and cost optimization rather than growth. This assignment suits professionals managing end-of-lifecycle products or developing expertise in rare/neglected disease segments where older antibiotics retain clinical utility.
Worked on THIOSULFIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.